Mar Pérez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mar Pérez has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Jesús Avila
Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049 Madrid, Spain
32 shared publications - Félix Hernández
Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049 Madrid, Spain
24 shared publications Jesús Avila
Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain
12 shared publications- Ismael Santa-Maria
Centro de Biología Molecular “Severo Ochoa” CSIC/UAM, Facultad de Ciencias, Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain
8 shared publications Raquel Cuadros
Centro de Biología Molecular Severo Ochoa (CBMSO) CSIC-UAM, Madrid, Spain
8 shared publications- Jose Javier Lucas
Centro de Biología Molecular Severo Ochoa (CBM), CSIC – Universidad Autónoma de Madrid, Madrid, Spain
7 shared publications
Latest Publications
- Open Access
- 30 June 2023
- Published by Open Exploration Publishing
- Vol. 3 (3) , 151-163
Looking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy
Currently, the predominant targets for the treatment of Alzheimer’s disease (AD) are the main components of the two pathological structures: senile plaques (composed of amyloid beta peptide aggregates) or neurofibrillary tangles (constructed of tau protein polymers). However, the existence of adequate disease modifiers based on such targets is discussed. In this special issue, it has been suggested to search for new possible targets for AD therapy. This contribution tries to analyze non-neuronal tissues (periphery) to identify potential factors (target) involved in the development of AD.
- 30 June 2023
- Published by Open Exploration Publishing
- Vol. 3 (3) , 151-163
Open AccessLooking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy
Currently, the predominant targets for the treatment of Alzheimer’s disease (AD) are the main components of the two pathological structures: senile plaques (composed of amyloid beta peptide aggregates) or neurofibrillary tangles (constructed of tau protein polymers). However, the existence of adequate disease modifiers based on such targets is discussed. In this special issue, it has been suggested to search for new possible targets for AD therapy. This contribution tries to analyze non-neuronal tissues (periphery) to identify potential factors (target) involved in the development of AD.
- Open Access
Regulatory effects of miRNA-19a on MAD2 expression and tumorigenesis in gastric cancer
MAD2 is a key mitotic checkpoint protein that when overexpressed provokes chromosomal instability in gastric cancer. In this work, we used in silico analysis in combination with in vitro studies and clinical data to explore if miRNAs can regulate MAD2 at post-transcriptional level. By in silico analysis, we discriminate the expression of miRNAs between tumor and normal tissue, finding miR-19a and miR-203 targeted to 3’UTR MAD2L1 . Luciferase Assays proved that those miR’s are specific to MAD2L1 in human cells. RT-qPCR showed an inverse correlation between the expression miRNA19 and 203 and MAD2L1 in a panel of gastric cancer cell lines and in a pilot series of patients’ study. The miR-19a expression reduces the migration ability of AGS cells and invasion in MKN45 cells. Furthermore, the expression of the miRNA in combination with mitotic checkpoint drugs increase apoptosis. Finally, the TCGA analysis showed that Gastric Cancer patients with overexpression of MAD2, showed higher overall survival when miR-19a was overexpressed. Together, our results defined miR-19a as a critical regulator of MAD2 protein in Gastric Cancer and could potentially be used as a prognostic biomarker in clinical use.
Open AccessRegulatory effects of miRNA-19a on MAD2 expression and tumorigenesis in gastric cancer
MAD2 is a key mitotic checkpoint protein that when overexpressed provokes chromosomal instability in gastric cancer. In this work, we used in silico analysis in combination with in vitro studies and clinical data to explore if miRNAs can regulate MAD2 at post-transcriptional level. By in silico analysis, we discriminate the expression of miRNAs between tumor and normal tissue, finding miR-19a and miR-203 targeted to 3’UTR MAD2L1 . Luciferase Assays proved that those miR’s are specific to MAD2L1 in human cells. RT-qPCR showed an inverse correlation between the expression miRNA19 and 203 and MAD2L1 in a panel of gastric cancer cell lines and in a pilot series of patients’ study. The miR-19a expression reduces the migration ability of AGS cells and invasion in MKN45 cells. Furthermore, the expression of the miRNA in combination with mitotic checkpoint drugs increase apoptosis. Finally, the TCGA analysis showed that Gastric Cancer patients with overexpression of MAD2, showed higher overall survival when miR-19a was overexpressed. Together, our results defined miR-19a as a critical regulator of MAD2 protein in Gastric Cancer and could potentially be used as a prognostic biomarker in clinical use.
- Open Access
- 15 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (18) , 6749
Protein Biomarkers for the Diagnosis of Alzheimer’s Disease at Different Stages of Neurodegeneration
Mainly obtained from familial Alzheimer’s disease patients’ data, we know that some features of the neurodegenerative start several years before the appearance of clinical symptoms. In this brief review, we comment on some molecular and cellular markers appearing at different stages of the disease, before or once the clinical symptoms are evident. These markers are present in biological fluids or could be identified by image techniques. The combined use of molecular and cellular markers will be of interest to determine the development of the different phases of the disease.
- 15 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (18) , 6749
Open AccessProtein Biomarkers for the Diagnosis of Alzheimer’s Disease at Different Stages of Neurodegeneration
Mainly obtained from familial Alzheimer’s disease patients’ data, we know that some features of the neurodegenerative start several years before the appearance of clinical symptoms. In this brief review, we comment on some molecular and cellular markers appearing at different stages of the disease, before or once the clinical symptoms are evident. These markers are present in biological fluids or could be identified by image techniques. The combined use of molecular and cellular markers will be of interest to determine the development of the different phases of the disease.
- Open Access
- 2 July 2019
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 13, 698
Propagation of Tau via Extracellular Vesicles
Extracellular vesicles (EVs), like exosomes, play a critical role in physiological processes, including synaptic transmission and nerve regeneration. However, exosomes in particular can also contribute to the development of neurodegenerative conditions such as Alzheimer’s disease (AD), Parkinson’s disease, and prion diseases. All of these disorders are characterized by protein aggregation and deposition in specific regions of the brain. Several lines of evidence indicate that protein in exosomes is released from affected neurons and propagated along neuroanatomically connected regions of the brain, thus spreading the neurodegenerative disease. Also, different cell types contribute to the progression of tauopathy, such as microglia. Several groups have reported tau release via exosomes by cultured neurons or cells overexpressing human tau. Although the exact mechanisms underlying the propagation of protein aggregates are not fully understood, recent findings have implicated EVs in this process. The AD brain has two hallmarks, namely the presence of amyloid-β-containing plaques and neurofibrillary tangles, the latter formed by hyperphosphorylated tau protein. Both amyloid peptide and tau protein are present in specific exosomes. This review summarizes recent advances in our understanding of exosomes in the pathology of AD, with a special focus on tau protein.
- 2 July 2019
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 13, 698
Open AccessPropagation of Tau via Extracellular Vesicles
Extracellular vesicles (EVs), like exosomes, play a critical role in physiological processes, including synaptic transmission and nerve regeneration. However, exosomes in particular can also contribute to the development of neurodegenerative conditions such as Alzheimer’s disease (AD), Parkinson’s disease, and prion diseases. All of these disorders are characterized by protein aggregation and deposition in specific regions of the brain. Several lines of evidence indicate that protein in exosomes is released from affected neurons and propagated along neuroanatomically connected regions of the brain, thus spreading the neurodegenerative disease. Also, different cell types contribute to the progression of tauopathy, such as microglia. Several groups have reported tau release via exosomes by cultured neurons or cells overexpressing human tau. Although the exact mechanisms underlying the propagation of protein aggregates are not fully understood, recent findings have implicated EVs in this process. The AD brain has two hallmarks, namely the presence of amyloid-β-containing plaques and neurofibrillary tangles, the latter formed by hyperphosphorylated tau protein. Both amyloid peptide and tau protein are present in specific exosomes. This review summarizes recent advances in our understanding of exosomes in the pathology of AD, with a special focus on tau protein.
- Open Access
- 22 January 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (1) , e0210864
Role of tau N-terminal motif in the secretion of human tau by End Binding proteins
For unknown reasons, humans appear to be particular susceptible to developing tau pathology leading to neurodegeneration. Transgenic mice are still undoubtedly the most popular and extensively used animal models for studying Alzheimer’s disease and other tauopathies. While these murine models generally overexpress human tau in the mouse brain or specific brain regions, there are differences between endogenous mouse tau and human tau protein. Among them, a main difference between human and mouse tau is the presence of a short motif spanning residues 18 to 28 in the human tau protein that is missing in murine tau, and which could be at least partially responsible for that different susceptibility across species. Here we report novel data using affinity chromatography analysis indicating that the sequence containing human tau residues 18 to 28 acts a binding motif for End Binding proteins and that this interaction could facilitate tau secretion to the extracellular space.
- 22 January 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (1) , e0210864
Open AccessRole of tau N-terminal motif in the secretion of human tau by End Binding proteins
For unknown reasons, humans appear to be particular susceptible to developing tau pathology leading to neurodegeneration. Transgenic mice are still undoubtedly the most popular and extensively used animal models for studying Alzheimer’s disease and other tauopathies. While these murine models generally overexpress human tau in the mouse brain or specific brain regions, there are differences between endogenous mouse tau and human tau protein. Among them, a main difference between human and mouse tau is the presence of a short motif spanning residues 18 to 28 in the human tau protein that is missing in murine tau, and which could be at least partially responsible for that different susceptibility across species. Here we report novel data using affinity chromatography analysis indicating that the sequence containing human tau residues 18 to 28 acts a binding motif for End Binding proteins and that this interaction could facilitate tau secretion to the extracellular space.
- Open Access
- 12 July 2018
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 12, 202
Frontotemporal Dementia-Associated N279K Tau Mutation Localizes at the Nuclear Compartment
Tau is a microtubule-associated protein that plays an important role in Alzheimer's disease and related tauopathies. Approximately one-half of all cases of Frontotemporal dementia with parkinsonism-17 (FTDP-17) are caused by mutations in the MAPT gene. The N279K mutation is one of the three mutations more prevalent in FTDP-17 cases. Several studies have demonstrated that N279K Tau mutation alters alternative splicing inducing the presence of exon10. Tau is mainly found in the cytosol of neuronal cells although it has also been localized within the nucleus. Here we demonstrate by biochemical and immunohistochemistry studies in COS-7 cells, that the proportion of mutant N279K Tau increases compared with wild-type at the cell nucleus although cell viability is not affected. These data will provide us with a better outline of the nuclear role of tau protein offering new clues related with this tauopathy.
- 12 July 2018
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 12, 202
Open AccessFrontotemporal Dementia-Associated N279K Tau Mutation Localizes at the Nuclear Compartment
Tau is a microtubule-associated protein that plays an important role in Alzheimer's disease and related tauopathies. Approximately one-half of all cases of Frontotemporal dementia with parkinsonism-17 (FTDP-17) are caused by mutations in the MAPT gene. The N279K mutation is one of the three mutations more prevalent in FTDP-17 cases. Several studies have demonstrated that N279K Tau mutation alters alternative splicing inducing the presence of exon10. Tau is mainly found in the cytosol of neuronal cells although it has also been localized within the nucleus. Here we demonstrate by biochemical and immunohistochemistry studies in COS-7 cells, that the proportion of mutant N279K Tau increases compared with wild-type at the cell nucleus although cell viability is not affected. These data will provide us with a better outline of the nuclear role of tau protein offering new clues related with this tauopathy.
- 12 June 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 64 (s1) , S529-S534
New Beginnings in Alzheimer’s Disease: The Most Prevalent Tauopathy
Alzheimer’s disease (AD) is characterized by the presence of two aberrant structures: namely senile plaques, composed of amyloid-β peptide (Aβ), and neurofibrillary tangles, composed of tau protein. In this regard, Aβ and tau protein have been widely
- 12 June 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 64 (s1) , S529-S534
New Beginnings in Alzheimer’s Disease: The Most Prevalent Tauopathy
Alzheimer’s disease (AD) is characterized by the presence of two aberrant structures: namely senile plaques, composed of amyloid-β peptide (Aβ), and neurofibrillary tangles, composed of tau protein. In this regard, Aβ and tau protein have been widely
- 8 June 2018
- Published by Springer Nature
- Vol. 1779, 447-461
Tau Assembly into Filaments
The brain-specific tau protein binds directly through microtubules to regulate dynamically its structure and function. It also plays a critical role in the pathogenesis of a number of neurodegenerative disorders collectively known as tauopathies, the most common of which is Alzheimer’s disease (AD). Under pathological conditions, the natively unfolded tau protein self-assembles into filamentous structures of aggregated, hyperphosphorylated tau. In AD brains, tau accumulates in the neuronal perikarya and processes as paired helical filaments (PHF) forming the neurofibrillary tangles (NFT) characteristic of the disease. Prominent tau neurofibrillary pathology is a common feature in all tauopathies and its development is associated with progressive neuronal loss and cognitive decline. A precise understanding of the cellular, biochemical, and structural mechanisms involved in the process of tau protein aggregation and fibril formation is key to design strategies to prevent, slow down, or stop the neurodegenerative pathway leading to neuronal loss in AD and other tauopathies. Herein, we describe some complementary experimental procedures for PHF purification from human postmortem brain, tau expression and purification, as well as in vitro formation of tau filaments from purified recombinant tau.
- 8 June 2018
- Published by Springer Nature
- Vol. 1779, 447-461
Tau Assembly into Filaments
The brain-specific tau protein binds directly through microtubules to regulate dynamically its structure and function. It also plays a critical role in the pathogenesis of a number of neurodegenerative disorders collectively known as tauopathies, the most common of which is Alzheimer’s disease (AD). Under pathological conditions, the natively unfolded tau protein self-assembles into filamentous structures of aggregated, hyperphosphorylated tau. In AD brains, tau accumulates in the neuronal perikarya and processes as paired helical filaments (PHF) forming the neurofibrillary tangles (NFT) characteristic of the disease. Prominent tau neurofibrillary pathology is a common feature in all tauopathies and its development is associated with progressive neuronal loss and cognitive decline. A precise understanding of the cellular, biochemical, and structural mechanisms involved in the process of tau protein aggregation and fibril formation is key to design strategies to prevent, slow down, or stop the neurodegenerative pathway leading to neuronal loss in AD and other tauopathies. Herein, we describe some complementary experimental procedures for PHF purification from human postmortem brain, tau expression and purification, as well as in vitro formation of tau filaments from purified recombinant tau.
- Open Access
- 1 January 2018
- Published by Walter de Gruyter GmbH in BioMolecular Concepts
- Vol. 9 (1) , 1-11
Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro
The microtubule-associated protein Tau plays a crucial role in stabilizing neuronal microtubules. In Tauopathies, Tau loses its ability to bind microtubules, detach from them and forms intracellular aggregates. Increasing evidence in recent years supports the notion that Tau pathology spreading throughout the brain in AD and other Tauopathies is the consequence of the propagation of specific Tau species along neuroanatomically connected brain regions in a so-called “prion-like” manner. A number of steps are assumed to be involved in this process, including secretion, cellular uptake, transcellular transfer and/or seeding, although the precise mechanisms underlying propagation of Tau pathology are not fully understood yet. This review summarizes recent evidence on the nature of the specific Tau species that are propagated and the different mechanisms of Tau pathology spreading.
- 1 January 2018
- Published by Walter de Gruyter GmbH in BioMolecular Concepts
- Vol. 9 (1) , 1-11
Open AccessSecretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro
The microtubule-associated protein Tau plays a crucial role in stabilizing neuronal microtubules. In Tauopathies, Tau loses its ability to bind microtubules, detach from them and forms intracellular aggregates. Increasing evidence in recent years supports the notion that Tau pathology spreading throughout the brain in AD and other Tauopathies is the consequence of the propagation of specific Tau species along neuroanatomically connected brain regions in a so-called “prion-like” manner. A number of steps are assumed to be involved in this process, including secretion, cellular uptake, transcellular transfer and/or seeding, although the precise mechanisms underlying propagation of Tau pathology are not fully understood yet. This review summarizes recent evidence on the nature of the specific Tau species that are propagated and the different mechanisms of Tau pathology spreading.
- 1 November 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 634, 63-69
Secretion of full-length tau or tau fragments in a cell culture model
- 1 November 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 634, 63-69
Secretion of full-length tau or tau fragments in a cell culture model